The effect of green tea tablets in the treatment of polycystic ovary syndrome.

Effect of green tea tablet on inflammatory markers C-reactive protein, interleukin-6, tumor necrosis factor alpha, insulin, fasting blood glucose and blood lipid profile in women with polycystic ovary syndrome.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015021816123N4

Enrollment

Registered

2015-03-11

Start date

2015-03-08

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome. Stein-Leventhal syndrome

Interventions

Intervention 1: Intervention: diet controlling

tablets containing 50 mg of green tea polyphenols 4 per day for 45 days. Intervention 2: Control:diet controlling for 45 days .

Treatment - Other

Intervention: diet controlling

tablets containing 50 mg of green tea polyphenols 4 per day for 45 days.

Control:diet controlling for 45 days .

Eligibility

Sex/Gender

Female

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age 55-18, 40-25 Body Mass Index, a willingness to participate in the study,having two features of the following three characteristics: oligo ovulation or anovulation, clinical or biochemical evidence of hyperandrogenism,having more than 12 but less than 10 mm immature follicles in each ovary. Exclusion criteria: no appropriate corporation; any other disease, pregnancy and lactating

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting blood glucose. Timepoint: at the first and at the end of intervention period. Method of measurement: Autoanalyzer.;Insulin level. Timepoint: at the first and at the end of intervention period. Method of measurement: Autoanalyzer.;LDL. Timepoint: at the first and at the end of intervention period. Method of measurement: Autoanalyzer.;HDL. Timepoint: at the first and at the end of intervention period. Method of measurement: Autoanalyzer.;TG. Timepoint: at the first and at the end of intervention period. Method of measurement: Autoanalyzer.;Total Cholesterol. Timepoint: at the first and at the end of intervention period. Method of measurement: Autoanalyzer.;Hs-CRP. Timepoint: at the first and at the end of intervention period. Method of measurement: Elisa.;IL-6. Timepoint: at the first and at the end of intervention period. Method of measurement: Elisa.;TNF-a. Timepoint: at the first and at the end of intervention period. Method of measurement: Elisa.	—

Measure

Time frame

Fasting blood glucose. Timepoint: at the first and at the end of intervention period. Method of measurement: Autoanalyzer.;Insulin level. Timepoint: at the first and at the end of intervention period. Method of measurement: Autoanalyzer.;LDL. Timepoint: at the first and at the end of intervention period. Method of measurement: Autoanalyzer.;HDL. Timepoint: at the first and at the end of intervention period. Method of measurement: Autoanalyzer.;TG. Timepoint: at the first and at the end of intervention period. Method of measurement: Autoanalyzer.;Total Cholesterol. Timepoint: at the first and at the end of intervention period. Method of measurement: Autoanalyzer.;Hs-CRP. Timepoint: at the first and at the end of intervention period. Method of measurement: Elisa.;IL-6. Timepoint: at the first and at the end of intervention period. Method of measurement: Elisa.;TNF-a. Timepoint: at the first and at the end of intervention period. Method of measurement: Elisa.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026